How Cell State Shapes KRAS Mutation Effects in Pancreatic Cancer

In this study, the researchers asked whether different mutant versions of the KRAS gene—which is altered in over 90% of pancreatic ductal adenocarcinomas (PDAC), an aggressive form of pancreatic cancer—drive unique molecular programs in cancer cells.

The researchers used CRISPR/Cas9 gene editing—a precise molecular tool for modifying DNA—to remove KRAS from two human PDAC cell lines, then reintroduced wild-type or seven common mutant KRAS variants at comparable expression levels. They profiled the resulting cells using RNA sequencing (to measure gene activity) and mass spectrometry–based proteomics and phosphoproteomics (to measure protein abundance and activity). This multi-omics approach captured molecular changes across four genetically matched cell line series.

Cell line identity—not which KRAS mutation was present—was the dominant source of molecular variation, accounting for 49%–57% of variance in the transcriptome and proteome, while KRAS allele identity explained only 3%–5%. No robust mutation-specific transcriptomic, proteomic, or phosphoproteomic signatures were identified, indicating that the different KRAS mutations are more similar than different. Across all mutants, shared changes included suppression of interferon response genes and increased activity of ERK1/2—a key enzyme that relays signals controlling cell growth—alongside reduced activity of DYRK enzymes, which have been linked to resistance to ERK inhibition.

The authors note that their in vitro system (experiments conducted in cells outside a living organism) does not capture the microenvironmental and evolutionary pressures that may differentially select for specific KRAS alleles during tumor development in vivo (inside a living organism). They call for further experimental validation to determine how cellular state and microenvironmental cues intersect with KRAS allele identity to shape tumor biology and therapeutic response.